Watch ANVS. Know when insiders buy.
One email the day a filing lands. Free.
ANVS
Annovis Bio, Inc.
1.39
+0.01 +0.72%
USD · close Sep 4
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
62
WATCH · shorts 62
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $59.2MP/E —DIV YIELD —FCF YIELD —REV TTM $0NET INCOME −$49.5MNET CASH —52W 1.38 – 5.10SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $0 | — | — | −$14.4M | −$14.8M | — | -0.40 | −$21.9M | — | — | Aug 14 |
| Q1 2026 · Mar 31 | $0 | — | — | −$18M | −$17.6M | — | -0.63 | −$9M | — | — | Aug 14 |
| Q4 2025 · Dec 31derived | $0 | — | — | −$9.7M | −$9.8M | — | -0.39 | −$8.9M | — | — | Mar 13 |
| Q3 2025 · Sep 30 | $0 | — | — | −$7.4M | −$7.3M | — | -0.37 | −$3.5M | — | — | Nov 12 |
| Q2 2025 · Jun 30 | $0 | — | — | −$6.3M | −$6.2M | — | -0.32 | −$5.1M | — | — | Aug 14 |
| Q1 2025 · Mar 31 | $0 | — | — | −$6.3M | −$5.5M | — | -0.32 | −$8.1M | — | — | Aug 14 |
| Q4 2024 · Dec 31derived | $0 | — | — | −$6.7M | −$5.9M | — | -0.42 | −$8.3M | — | — | Mar 13 |
| Q3 2024 · Sep 30 | $0 | — | — | −$4.4M | −$12.6M | — | -0.97 | −$3.2M | — | — | Nov 12 |
| Q2 2024 · Jun 30 | $0 | — | — | −$7.8M | −$5M | — | -0.44 | −$3.4M | — | — | Nov 12 |
| Q1 2024 · Mar 31 | $0 | — | — | −$7.8M | −$1.1M | — | -0.72 | −$7M | — | — | Nov 12 |
| Q4 2023 · Dec 31derived | $0 | — | — | −$10.4M | −$22.2M | — | -2.33 | −$9.4M | — | — | Mar 21 |
| Q3 2023 · Sep 30 | $0 | — | — | −$14.9M | −$14.7M | — | -1.63 | −$9.4M | — | — | Nov 8 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $0 | — | −$29.7M | −$28.9M | — | -1.40 | −$25.6M | — | — | — | — |
| FY2024 · to Dec 31 | $0 | — | −$26.7M | −$24.6M | — | -2.31 | −$21.9M | — | — | — | — |
| FY2023 · to Dec 31 | $0 | — | −$45M | −$56.2M | — | -6.23 | −$40M | — | — | — | — |
| FY2022 · to Dec 31 | $0 | — | −$25.5M | −$25.3M | — | -3.10 | −$17.3M | — | — | — | — |
| FY2021 · to Dec 31 | $0 | — | −$14.5M | −$14.5M | — | -1.90 | −$9.1M | — | — | — | — |
| FY2020 · to Dec 31 | $0 | — | −$6.6M | −$5.5M | — | -0.87 | −$4M | — | — | — | — |
Every number comes from Annovis Bio, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.